103 related articles for article (PubMed ID: 33191818)
21. Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes.
Potmešil P; Szotkowská R
Ther Adv Chronic Dis; 2020; 11():2040622320964152. PubMed ID: 33240477
[TBL] [Abstract][Full Text] [Related]
22. Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
Braha A; Albai A; Timar R; Diaconu L; Vasiluță L; Cipu D; Timar B; Sima A
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238573
[TBL] [Abstract][Full Text] [Related]
23. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Komorizono Y; Hosoyamada K; Imamura N; Kajiya S; Hashiguchi Y; Ueyama N; Shinmaki H; Koriyama N; Tsukasa M; Kamada T
Diabetes Obes Metab; 2021 Mar; 23(3):832-837. PubMed ID: 33236464
[TBL] [Abstract][Full Text] [Related]
24. Application of supercritical fluid chromatography for separation and quantitation of 15 co-formulated binary anti-hypertensive medications using a single elution protocol.
Pandya PA; Shah PA; Shrivastav PS
Biomed Chromatogr; 2021 Apr; 35(4):e5035. PubMed ID: 33226650
[TBL] [Abstract][Full Text] [Related]
25. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial.
Bae J; Huh JH; Lee M; Lee YH; Lee BW
Diabetes Obes Metab; 2021 Feb; 23(2):609-618. PubMed ID: 33217092
[TBL] [Abstract][Full Text] [Related]
26. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis.
Chewcharat A; Prasitlumkum N; Thongprayoon C; Bathini T; Medaura J; Vallabhajosyula S; Cheungpasitporn W
Med Sci (Basel); 2020 Nov; 8(4):. PubMed ID: 33213078
[TBL] [Abstract][Full Text] [Related]
28. The potential effects of clinical antidiabetic agents on SARS-CoV-2.
Qu H; Zheng Y; Wang Y; Li H; Liu X; Xiong X; Zhang L; Gu J; Yang G; Zhu Z; Zheng H; Ouyang Q
J Diabetes; 2021 Mar; 13(3):243-252. PubMed ID: 33210826
[TBL] [Abstract][Full Text] [Related]
29. Non-antibiotic medication use in an Indonesian community cohort 0-18 months of age.
At Thobari J; Satria CD; Ridora Y; Watts E; Handley A; Standish J; Bachtiar NS; Buttery JP; Soenarto Y; Bines JE
PLoS One; 2020; 15(11):e0242410. PubMed ID: 33206684
[TBL] [Abstract][Full Text] [Related]
30. A Giant Right-Heart Thrombus-in-Transit in a Patient with COVID-19 Pneumonia.
Khan HMW; Khan MR; Munir A; Moughrabieh A; Changezi HU
Am J Case Rep; 2020 Nov; 21():e927380. PubMed ID: 33201863
[TBL] [Abstract][Full Text] [Related]
31. Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation.
Inage K; Sainoh T; Fujiyoshi T; Otagiri T; Aoki Y; Inoue M; Eguchi Y; Orita S; Shiga Y; Koda M; Akazawa T; Furuya T; Nakamura J; Takahashi H; Suzuki M; Maki S; Kinoshita H; Norimoto M; Umimura T; Sato T; Sato M; Suzuki M; Enomoto K; Takaoka H; Mizuki N; Hozumi T; Tsuchiya R; Kim G; Mukaihata T; Hishiya T; Ohtori S
Spine Surg Relat Res; 2020; 4(4):354-357. PubMed ID: 33195861
[TBL] [Abstract][Full Text] [Related]
32. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
Yang AY; Chen HC
Int J Clin Pharm; 2021 Aug; 43(4):1015-1023. PubMed ID: 33258006
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Clinical and Laboratory Features and Treatment Options of 237 Symptomatic and Asymptomatic Children Infected with SARS-CoV-2 in the Early Phase of the COVID-19 Pandemic in Turkey.
Soysal A; Gönüllü E; Arslan H; Kibar BS; Pop S; Yurttaş GN; Demirbacak H; Ünal F; Öktem S; Atıcı S; Yücel Şen AD; Karabayır N; Karaböcüoğlu M;
Jpn J Infect Dis; 2021 Jul; 74(4):273-279. PubMed ID: 33250495
[TBL] [Abstract][Full Text] [Related]
34. Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database.
Levin LE; Shayegan LH; Lucky AW; Hook KP; Bruckner AL; Feinstein JA; Whittier S; Lauren CT; Pope E; Lara-Corrales I; Wiss K; McCuaig CC; Powell J; Eichenfield LF; Levy ML; Diaz L; Glick SA; Paller AS; Price HN; Browning JC; Morel KD
Pediatr Dermatol; 2021 Jan; 38(1):119-124. PubMed ID: 33247481
[TBL] [Abstract][Full Text] [Related]
35. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes.
Takahara M; Shiraiwa T; Matsuoka TA; Yamamoto K; Maeno Y; Shiraiwa Y; Yoshida Y; Katakami N; Iijima H; Katsumata H; Arakawa K; Hashimoto T; Shimomura I
Diabetes Metab Syndr Obes; 2020; 13():4457-4468. PubMed ID: 33244248
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Cardiovascular Safety of Sulfonylureas.
Fernandez CJ; Raveendran AV; Htwe N
Curr Drug Saf; 2021; 16(2):142-153. PubMed ID: 33243129
[TBL] [Abstract][Full Text] [Related]
38. Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study.
Maloberti A; Bombelli M; Facchetti R; Barbagallo CM; Bernardino B; Rosei EA; Casiglia E; Cicero AFG; Cirillo M; Cirillo P; Desideri G; D'elia L; Dell'Oro R; Ferri C; Galletti F; Giannattasio C; Loreto G; Iaccarino G; Lippa L; Mallamaci F; Masi S; Mazza A; Muiesan ML; Nazzaro P; Parati G; Palatini P; Pauletto P; Pontremoli R; Quarti-Trevano F; Rattazzi M; Rivasi G; Salvetti M; Tikhonoff V; Tocci G; Ungar A; Verdecchia P; Viazzi F; Volpe M; Virdis A; Grassi G; Borghi C;
J Hypertens; 2021 Feb; 39(2):333-340. PubMed ID: 33239553
[TBL] [Abstract][Full Text] [Related]
39. GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.
Pablo A; Evelyn B; Claudia F; Yanina MA
Curr Hypertens Rev; 2021; 17(2):149-158. PubMed ID: 33238857
[TBL] [Abstract][Full Text] [Related]
40. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid.
Tedeschi A; Agostoni P; Pezzuto B; Corra' U; Scrutinio D; La Gioia R; Raimondo R; Passantino A; Piepoli MF
Eur J Prev Cardiol; 2020 Dec; 27(2_suppl):35-45. PubMed ID: 33238740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
